| Q44442996 | A cannabinoid agonist differentially attenuates deep tissue hyperalgesia in animal models of cancer and inflammatory muscle pain |
| Q41839263 | Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats |
| Q60679661 | Analgesic Effects of Fatty Acid Amide Hydrolase Inhibition in a Rat Model of Neuropathic Pain |
| Q34924520 | Analgesic and antiinflammatory effects of cannabinoid receptor agonists in a rat model of neuropathic pain |
| Q48200053 | CB1 receptor activation in the basolateral amygdala produces antinociception in animal models of acute and tonic nociception. |
| Q43678224 | CB1 receptor mediated analgesia from the Nucleus Reticularis Gigantocellularis pars alpha is activated in an animal model of neuropathic pain |
| Q53113293 | Cannabidiol-Δ9-tetrahydrocannabinol interactions on acute pain and locomotor activity. |
| Q28345158 | Cannabinoid actions on rat superficial medullary dorsal horn neurons in vitro |
| Q45072828 | Cannabinoid agonist, CP 55,940, prevents capsaicin-induced sensitization of spinal cord dorsal horn neurons |
| Q31522100 | Cannabinoid receptor ligands: clinical and neuropharmacological considerations, relevant to future drug discovery and development |
| Q28143655 | Cannabinoid receptors and pain |
| Q46500131 | Cannabinoid-induced effects on the nociceptive system: a neurophysiological study in patients with secondary progressive multiple sclerosis |
| Q44691670 | Cannabinoid-induced presynaptic inhibition at the primary afferent trigeminal synapse of juvenile rat brainstem slices. |
| Q41586486 | Continuous infusion of the cannabinoid WIN 55,212-2 to the site of a peripheral nerve injury reduces mechanical and cold hypersensitivity |
| Q64096813 | Core Outcome Measures in Preclinical Assessment of Candidate Analgesics |
| Q43028756 | Differential contribution of opioid and noradrenergic mechanisms of tapentadol in rat models of nociceptive and neuropathic pain. |
| Q48433166 | Effects of a cannabinoid agonist on spinal nociceptive neurons in a rodent model of neuropathic pain |
| Q36711160 | Endocannabinoid mechanisms of pain modulation |
| Q33936628 | Endothelin-A receptor antagonism attenuates carcinoma-induced pain through opioids in mice |
| Q41958365 | Gz mediates the long-lasting desensitization of brain CB1 receptors and is essential for cross-tolerance with morphine |
| Q34320139 | Hu 210: a potent tool for investigations of the cannabinoid system. |
| Q37444813 | Interaction of the cannabinoid and opioid systems in the modulation of nociception |
| Q40680337 | Long-term interactions between opioid and cannabinoid agonists at the cellular level: cross-desensitization and downregulation |
| Q39363705 | Molecular mechanisms involved in the asymmetric interaction between cannabinoid and opioid systems |
| Q37407417 | Peripheral cannabinoids attenuate carcinoma-induced nociception in mice |
| Q34434597 | Pharmacological actions and therapeutic uses of cannabis and cannabinoids. |
| Q34430635 | Possible mechanisms of cannabinoid-induced antinociception in the spinal cord |
| Q33527067 | Recent data on cannabinoids and their pharmacological implications in neuropathic pain |
| Q37345505 | Repeated cannabinoid injections into the rat periaqueductal gray enhance subsequent morphine antinociception |
| Q41862326 | Repeated treatment with the synthetic cannabinoid WIN 55,212-2 reduces both hyperalgesia and production of pronociceptive mediators in a rat model of neuropathic pain |
| Q36726650 | Role of the cannabinoid system in pain control and therapeutic implications for the management of acute and chronic pain episodes |
| Q34161442 | Skin β-endorphin mediates addiction to UV light |
| Q34731928 | Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial |
| Q35035850 | Spinal and peripheral mechanisms of cannabinoid antinociception: behavioral, neurophysiological and neuroanatomical perspectives |
| Q38600704 | The Endogenous Cannabinoid System: A Budding Source of Targets for Treating Inflammatory and Neuropathic Pain. |
| Q39697570 | The effect of spinally administered WIN 55,212-2, a cannabinoid agonist, on thermal pain sensitivity in diabetic rats |
| Q60690604 | The endocannabinoid and endovanilloid systems and their interactions in neuropathic pain |
| Q34305854 | The endocannabinoid nervous system: unique opportunities for therapeutic intervention |
| Q28366593 | The synthetic cannabinoid WIN55,212-2 attenuates hyperalgesia and allodynia in a rat model of neuropathic pain |
| Q36187065 | Therapeutic potential of cannabinoid receptor agonists as analgesic agents |